Some very interesting developments recently. Yesterday filing revealed a new interest.
MONTSANT PARTNERS LLC
DELAWARE LIMITED-LIABILITY COMPANY (LLC)
http://www.bizapedia.com/de/MONTSANT-PARTNERS-LLC.html
Company Name: MONTSANT PARTNERS LLC
File Number: 5400485
Filing State: Delaware (DE)
Filing Status: Unknown
Filing Date: September 17, 2013
Company Age: 1 Year 11 Months
Registered Agent:
W/K Incorporating Services, Inc.
3500 S Dupont Hwy
Dover, DE 19901
==============================
SECURITIES EXCHANGE AGREEMENT
This SECURITIES EXCHANGE AGREEMENT dated as of August 20, 2015 (this “Agreement”) is made by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Montsant Partners LLC, a Delaware limited liability company (“Montsant”), and Platinum Partners Value Arbitrage Fund, L.P. (“Platinum” and, together with Montsant, the “Investors”).
Recitals
A. The Investors hold an aggregate of 4,519 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Shares”), that are currently convertible into an aggregate of 14,777,130 shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”).
B. The Company has requested that the Investors exchange their respective Series B Shares for Warrants to acquire an aggregate of 14,777,130 shares of Common Stock at an exercise price per share of $0.01 per share.
C. The Investors are willing to so exchange their Series B Shares on the terms and conditions set forth herein.
http://www.sec.gov/Archives/edgar/data/810509...ex10-1.htm
======================================
(i) This Warrant shall be deemed to have been exercised in full upon the earlier to occur of either of the following (each, an “Automatic Exercise Event”): (i) the closing of a firm commitment underwritten public offering of Common Stock of the Issuer pursuant to an effective registration statement under Section 5 of the Securities Act in which the gross cash proceeds to the Issuer (before underwriting discounts, commissions and fees) from such public offering are at least $10,000,000, or (ii) one hundred eighty (180) days following the first Trading Date upon which the Trigger Price per share of the Common Stock equals or exceeds $7.00 per share, but excluding from such 180 day period any Trading Day on which the Trigger Price is less than $5.00 per share. The number of shares of Common Stock which the Holder shall receive upon an Automatic Exercise Event shall be determined by applying the cashless exercise formula contained in Section 2(c), assuming the exercise in full of this Warrant.
http://www.sec.gov/Archives/edgar/data/810509...ex10-2.htm
=============================================
Navidea Biopharmaceuticals to Register Shares for Dual Listing on Tel-Aviv Stock Exchange
http://finance.yahoo.com/news/navidea-biophar...00590.html
==================================
Institutionals
http://www.nasdaq.com/symbol/navb/institution...ngs?page=4
===========================
Manocept platform is coming along. Expecting an update soon as mentioned in the July 2nd PR for an end of summer update.
7-2-15 “We are very encouraged that our Manocept platform, with its unique ability to seek out activated macrophages, may selectively deliver a therapeutic that can kill tumor cells, tumor support cells and virus contained in the macrophage. This activity was seen with a therapeutic that without our delivery system would not be effective on the tumor, the TAM’s or either of the viruses. This data suggests that targeting the activated macrophage is a viable strategy for attacking cancers that have TAM’s. It is well established that depleting TAM’s makes the tumor more susceptible to chemotherapy, radiation therapy and many of the new and emerging immune therapy drugs. In addition the effect of this agent with no known anti-viral properties on killing both HIV and HHV8 suggests a novel anti-viral strategy that will not require development of specific tailored drugs to a given virus,” said Michael M. Goldberg, M.D., CEO of Macrophage Therapeutics and Director of Navidea. “We look forward to advancing development of our broad therapeutic platform through animal testing this summer in a number of solid tumor models as well as explore the potential of our technology in CNS diseases, viral diseases and animal models of auto-immune disease. Our goal is to seek strategic collaborations with industry leaders to enable rapid development. Finally, we will host an investor day at the end of the summer where we will review the accumulated data being generated.”
http://ir.navidea.com/phoenix.zhtml?c=68527&a...ID=2064425
MONTSANT PARTNERS LLC
DELAWARE LIMITED-LIABILITY COMPANY (LLC)
http://www.bizapedia.com/de/MONTSANT-PARTNERS-LLC.html
Company Name: MONTSANT PARTNERS LLC
File Number: 5400485
Filing State: Delaware (DE)
Filing Status: Unknown
Filing Date: September 17, 2013
Company Age: 1 Year 11 Months
Registered Agent:
W/K Incorporating Services, Inc.
3500 S Dupont Hwy
Dover, DE 19901
==============================
SECURITIES EXCHANGE AGREEMENT
This SECURITIES EXCHANGE AGREEMENT dated as of August 20, 2015 (this “Agreement”) is made by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Montsant Partners LLC, a Delaware limited liability company (“Montsant”), and Platinum Partners Value Arbitrage Fund, L.P. (“Platinum” and, together with Montsant, the “Investors”).
Recitals
A. The Investors hold an aggregate of 4,519 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Shares”), that are currently convertible into an aggregate of 14,777,130 shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”).
B. The Company has requested that the Investors exchange their respective Series B Shares for Warrants to acquire an aggregate of 14,777,130 shares of Common Stock at an exercise price per share of $0.01 per share.
C. The Investors are willing to so exchange their Series B Shares on the terms and conditions set forth herein.
http://www.sec.gov/Archives/edgar/data/810509...ex10-1.htm
======================================
(i) This Warrant shall be deemed to have been exercised in full upon the earlier to occur of either of the following (each, an “Automatic Exercise Event”): (i) the closing of a firm commitment underwritten public offering of Common Stock of the Issuer pursuant to an effective registration statement under Section 5 of the Securities Act in which the gross cash proceeds to the Issuer (before underwriting discounts, commissions and fees) from such public offering are at least $10,000,000, or (ii) one hundred eighty (180) days following the first Trading Date upon which the Trigger Price per share of the Common Stock equals or exceeds $7.00 per share, but excluding from such 180 day period any Trading Day on which the Trigger Price is less than $5.00 per share. The number of shares of Common Stock which the Holder shall receive upon an Automatic Exercise Event shall be determined by applying the cashless exercise formula contained in Section 2(c), assuming the exercise in full of this Warrant.
http://www.sec.gov/Archives/edgar/data/810509...ex10-2.htm
=============================================
Navidea Biopharmaceuticals to Register Shares for Dual Listing on Tel-Aviv Stock Exchange
http://finance.yahoo.com/news/navidea-biophar...00590.html
==================================
Institutionals
http://www.nasdaq.com/symbol/navb/institution...ngs?page=4
===========================
Manocept platform is coming along. Expecting an update soon as mentioned in the July 2nd PR for an end of summer update.
7-2-15 “We are very encouraged that our Manocept platform, with its unique ability to seek out activated macrophages, may selectively deliver a therapeutic that can kill tumor cells, tumor support cells and virus contained in the macrophage. This activity was seen with a therapeutic that without our delivery system would not be effective on the tumor, the TAM’s or either of the viruses. This data suggests that targeting the activated macrophage is a viable strategy for attacking cancers that have TAM’s. It is well established that depleting TAM’s makes the tumor more susceptible to chemotherapy, radiation therapy and many of the new and emerging immune therapy drugs. In addition the effect of this agent with no known anti-viral properties on killing both HIV and HHV8 suggests a novel anti-viral strategy that will not require development of specific tailored drugs to a given virus,” said Michael M. Goldberg, M.D., CEO of Macrophage Therapeutics and Director of Navidea. “We look forward to advancing development of our broad therapeutic platform through animal testing this summer in a number of solid tumor models as well as explore the potential of our technology in CNS diseases, viral diseases and animal models of auto-immune disease. Our goal is to seek strategic collaborations with industry leaders to enable rapid development. Finally, we will host an investor day at the end of the summer where we will review the accumulated data being generated.”
http://ir.navidea.com/phoenix.zhtml?c=68527&a...ID=2064425
